NO970221L - Humane nöytraliserende monoklonale antistoffer mot humant immunsviktvirus - Google Patents

Humane nöytraliserende monoklonale antistoffer mot humant immunsviktvirus

Info

Publication number
NO970221L
NO970221L NO970221A NO970221A NO970221L NO 970221 L NO970221 L NO 970221L NO 970221 A NO970221 A NO 970221A NO 970221 A NO970221 A NO 970221A NO 970221 L NO970221 L NO 970221L
Authority
NO
Norway
Prior art keywords
monoclonal antibodies
immunodeficiency virus
human
antibodies against
neutralizing monoclonal
Prior art date
Application number
NO970221A
Other languages
English (en)
Other versions
NO970221D0 (no
Inventor
Dennis R Burton
Carlos F Barbas
Richard A Lerner
Original Assignee
Scripps Research Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Inst filed Critical Scripps Research Inst
Publication of NO970221D0 publication Critical patent/NO970221D0/no
Publication of NO970221L publication Critical patent/NO970221L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • C07K16/1145—Env proteins, e.g. gp41, gp110/120, gp160, V3, principal neutralising domain [PND] or CD4-binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Radiology & Medical Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Socks And Pantyhose (AREA)
  • Knitting Of Fabric (AREA)

Abstract

Humane monoklonale antistoffer som immunreagerer med og nøytraliserer humant immunsviktvirus (HIV). Immun-terapeutiske og diagnostiske metoder for anvendelse av de monoklonale antistoffer, så vel som en cellelinje for produksjon av de monoklonale antistoffer, er også beskrevet.
NO970221A 1994-07-18 1997-01-17 Humane nöytraliserende monoklonale antistoffer mot humant immunsviktvirus NO970221L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/276,852 US5652138A (en) 1992-09-30 1994-07-18 Human neutralizing monoclonal antibodies to human immunodeficiency virus
PCT/US1995/008743 WO1996002273A1 (en) 1994-07-18 1995-07-11 Human neutralizing monoclonal antibodies to human immunodeficiency virus

Publications (2)

Publication Number Publication Date
NO970221D0 NO970221D0 (no) 1997-01-17
NO970221L true NO970221L (no) 1997-03-18

Family

ID=23058336

Family Applications (1)

Application Number Title Priority Date Filing Date
NO970221A NO970221L (no) 1994-07-18 1997-01-17 Humane nöytraliserende monoklonale antistoffer mot humant immunsviktvirus

Country Status (8)

Country Link
US (2) US5652138A (no)
EP (1) EP0777497A4 (no)
JP (1) JPH10505229A (no)
AU (1) AU706601B2 (no)
CA (1) CA2195454A1 (no)
FI (1) FI970198L (no)
NO (1) NO970221L (no)
WO (1) WO1996002273A1 (no)

Families Citing this family (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5652138A (en) * 1992-09-30 1997-07-29 The Scripps Research Institute Human neutralizing monoclonal antibodies to human immunodeficiency virus
US20030187247A1 (en) * 1992-09-30 2003-10-02 The Scripps Research Institute Human neutralizing monoclonal antibodies to human immunodeficiency virus
PT744958E (pt) 1994-01-31 2003-11-28 Univ Boston Bancos de anticorpos policlonais
US20060078561A1 (en) * 1994-01-31 2006-04-13 The Trustees Of Boston University Polyclonal antibody libraries
US5843882A (en) 1995-04-27 1998-12-01 The United States Of America As Represented By The Department Of Health And Human Services Antiviral proteins and peptides
US7048935B2 (en) 1995-04-27 2006-05-23 The United States Of America As Represented By The Department Of Health And Human Services Cyanovirin conjugates and matrix-anchored cyanovirin and related compositions and methods of use
US6428790B1 (en) 1995-04-27 2002-08-06 The United States Of America As Represented By The Secretary Department Of Health And Human Services Cyanovirin conjugates and matrix-anchored cyanovirin and related compositions and methods of use
US6987096B1 (en) 1995-04-27 2006-01-17 The United States Of America As Represented By The Department Of Health And Human Services Antiviral proteins and peptides, DNA coding sequences therefor, and uses thereof
US6780847B2 (en) 1995-04-27 2004-08-24 The United States Of America As Represented By The Department Of Health And Human Services Glycosylation-resistant cyanovirins and related conjugates, compositions, nucleic acids, vectors, host cells, methods of production and methods of using nonglycosylated cyanovirins
US6193982B1 (en) 1995-04-27 2001-02-27 The United States Of America As Represented By The Department Of Health & Human Services Anti-cyanovirin antibody with an internal image of gp120, a method of use thereof, and a method of using a cyanovirin to induce an immune response to gp120
US6265215B1 (en) * 1996-09-13 2001-07-24 Ludwig Institute For Cancer Research Isolated peptides which complex with HLA-Cw16 and uses thereof
AU771224B2 (en) 1998-07-13 2004-03-18 Board Of Regents, The University Of Texas System Cancer treatment methods using antibodies to aminophospholipids
EP1980617A1 (en) 1998-12-31 2008-10-15 Novartis Vaccines and Diagnostics, Inc. Improved expression of HIV polypeptides and production of virus-like particles
WO2000039304A2 (en) 1998-12-31 2000-07-06 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
US6914128B1 (en) * 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
US7883704B2 (en) * 1999-03-25 2011-02-08 Abbott Gmbh & Co. Kg Methods for inhibiting the activity of the P40 subunit of human IL-12
US6482928B1 (en) * 1999-04-13 2002-11-19 Aventis Pasteur Limited And University Of Toronto Fab′-epitope complex from HIV-1 cross-neutralizing monoclonal antibody 2F5
US20040063605A1 (en) * 2000-08-02 2004-04-01 Jesper Eugen-Olsen Composition and method for the treatment or prevention of hiv infection
US8568766B2 (en) 2000-08-24 2013-10-29 Gattadahalli M. Anantharamaiah Peptides and peptide mimetics to treat pathologies associated with eye disease
CA2441287C (en) 2001-03-22 2014-06-10 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Glycosylation-resistant cyanovirins and related conjugates, compositions, nucleic acids, vectors, host cells, methods of production and methods of using nonglycosylated cyanovirins
US20020146753A1 (en) * 2001-04-06 2002-10-10 Henrik Ditzel Autoantibodies to glucose-6-phosphate isomerase and their participation in autoimmune disease
WO2002090510A2 (en) * 2001-05-08 2002-11-14 Emory University Regulating immine responses using dendritic cells
CA2452015C (en) 2001-07-05 2012-07-03 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
US20030170614A1 (en) 2001-08-31 2003-09-11 Megede Jan Zur Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof
CA2463931A1 (en) * 2001-10-16 2003-04-24 The Government Of The United States Of America, Represented By The Secre Tary, Department Of Health And Human Services Broadly cross-reactive neutralizing antibodies against human immunodeficiency virus selected by env-cd4-co-receptor complexes
US7811992B2 (en) 2002-02-06 2010-10-12 Stasys Technologies, Inc. Anti-infarction molecules
US7939641B2 (en) 2002-04-09 2011-05-10 The Scripps Research Institute Motif-grafted hybrid polypeptides and uses thereof
US7803913B2 (en) * 2002-05-06 2010-09-28 The United States Of America As Represented By The Department Of Health And Human Services Identification of novel broadly cross-reactive neutralizing human monoclonal antibodies using sequential antigen panning of phage display libraries
CA2485120C (en) * 2002-05-06 2013-02-19 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Identification of novel broadly cross-reactive hiv-1 neutralizing human monoclonal antibodies
US7429360B2 (en) * 2002-05-28 2008-09-30 Autogenomics, Inc. Level-controlled pipette for automated analytic devices
AU2003243151A1 (en) * 2002-08-16 2004-03-03 Agensys, Inc. Nucleic acid and corresponding protein entitled 251p5g2 useful in treatment and detection of cancer
US7597936B2 (en) * 2002-11-26 2009-10-06 University Of Utah Research Foundation Method of producing a pigmented composite microporous material
JP4824312B2 (ja) * 2002-11-26 2011-11-30 ユニバーシティ オブ ユタ リサーチ ファンデーション 微小孔物質、被分析物の局在化及び定量の方法、並びに被分析物の局在化及び定量用物品
AU2003300870A1 (en) * 2002-12-11 2004-06-30 The Scripps Research Institute Immunogenic mutant human immunodeficiency virus gp120 polypeptides, and methods of using same
WO2004080284A2 (en) 2003-03-07 2004-09-23 Board Of Regents, The University Of Texas System Antibody-targeted photodynamic therapy
CA2525370A1 (en) * 2003-05-06 2004-11-25 The Scripps Research Institute Domain-exchanged binding molecules, methods of use and methods of production
US20060035242A1 (en) * 2004-08-13 2006-02-16 Michelitsch Melissa D Prion-specific peptide reagents
EP1711517A4 (en) 2004-01-21 2008-02-13 Univ Utah Res Found MUTANT NAv1.7 SODIUM CHANNEL AND ASSOCIATED METHODS
US8512959B2 (en) * 2004-02-09 2013-08-20 Northwestern University Monoclonal antibody based biomarker discovery and development platform
WO2006044410A2 (en) * 2004-10-14 2006-04-27 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services A32 monoclonal antibody fusion proteins for use as hiv inhibitors and vaccines
US20070292390A1 (en) * 2004-10-29 2007-12-20 Dimitrov Dimiter S Broadly Cross-Reactive Hiv-1 Neutralizing Human Monoclonal Antibodies
EP1831247B1 (en) 2004-12-29 2009-07-01 Seattle Biomedical Research Institute Hetero-oligomeric hiv envelope proteins
JP5162250B2 (ja) * 2005-01-13 2013-03-13 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド プリオン特異的ペプチド試薬を使用するｅｌｉｓａアッセイ
WO2006076683A2 (en) * 2005-01-13 2006-07-20 Novartis Vaccines And Diagnostics Inc. Isolation and detection of pathogenic prions
EP2025762A3 (en) 2006-01-17 2009-09-30 Health Research Inc. Heteroduplex tracking assay
AU2007223427A1 (en) * 2006-03-01 2007-09-13 University Of Utah Research Foundation Methods and compositions related to cyclic peptide synthesis
US8470965B2 (en) * 2006-03-01 2013-06-25 University Of Utah Research Foundation Methods and compositions related to cyclic peptide synthesis
US7492312B2 (en) * 2006-11-14 2009-02-17 Fam Adly T Multiplicative mismatched filters for optimum range sidelobe suppression in barker code reception
JP2010514839A (ja) * 2007-01-03 2010-05-06 バーナム インスティテュート フォー メディカル リサーチ クロット結合化合物に関連する方法および組成物
CA2674788A1 (en) 2007-01-08 2008-07-17 Government Of The Usa, As Represented By The Secretary, Department Of He Alth And Human Services Slco1b3 genotype
AU2008205512B2 (en) 2007-01-16 2014-06-12 Abbvie Inc. Methods for treating psoriasis
NZ598881A (en) * 2007-03-29 2013-11-29 Abbvie Inc Crystalline anti-human il-12 antibodies
CA2687024A1 (en) 2007-05-09 2009-02-19 Burnham Institute For Medical Research Targeting host proteinases as a therapeutic strategy against viral and bacterial pathogens
MX2009012676A (es) 2007-05-23 2010-02-12 Uab Research Foundation Neuraminidasa neumococica no toxica y sus usos.
WO2009026496A1 (en) * 2007-08-22 2009-02-26 University Of Southern California Grp78 and tumor angiogenesis
US8557767B2 (en) 2007-08-28 2013-10-15 Uab Research Foundation Synthetic apolipoprotein E mimicking polypeptides and methods of use
EP2195331B1 (en) 2007-08-28 2013-11-20 Uab Research Foundation Synthetic apolipoprotein e mimicking polypeptides and methods of use
CA2706317C (en) * 2007-12-03 2017-06-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Doc1 compositions and methods for treating cancer
BRPI0908715A2 (pt) 2008-03-18 2016-05-03 Abbott Lab métodos para tratamento da psoríase
BRPI0910550A2 (pt) * 2008-04-30 2015-09-29 Novartis Ag ensaio para confôrmeros patogênicos
AU2008360658B2 (en) 2008-08-15 2015-02-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services S0X9, prostaglandin D2 and retinoic acid for treating pigmentary conditions and melanoma
US20120128684A1 (en) 2008-08-25 2012-05-24 Burnham Institute For Medical Research Conserved Hemagglutinin Epitope, Antibodies to the Epitope and Methods of Use
MX2011005672A (es) * 2008-11-28 2011-06-20 Abbott Lab Composiciones de anticuerpo estables y metodos para estabilizar a las mismas.
US20120070443A1 (en) 2008-12-02 2012-03-22 University Of Utah Research Foundation Pde1 as a target therapeutic in heart disease
WO2011020107A2 (en) 2009-08-14 2011-02-17 Georgetown University Compositions and methods for detection and treatment of breast cancer
AU2010291927A1 (en) 2009-09-14 2012-04-12 AbbVie Deutschland GmbH & Co. KG Methods for treating psoriasis
US20110081293A1 (en) 2009-10-07 2011-04-07 Sanford-Burnham Medical Research Institute Methods and compositions related to clot-binding lipid compounds
WO2011075725A1 (en) 2009-12-18 2011-06-23 Sanford-Burnham Medical Research Institute Methods and compositions related to clot-binding compounds
BR112012017483A2 (pt) 2010-01-14 2019-09-24 Haplomics Inc previsão e redução de aloimunogenicidade de terapêuticos de proteína
US20110207789A1 (en) 2010-02-19 2011-08-25 Ye Fang Methods related to casein kinase ii (ck2) inhibitors and the use of purinosome-disrupting ck2 inhibitors for anti-cancer therapy agents
WO2011119920A2 (en) 2010-03-25 2011-09-29 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
EP2569335B1 (en) 2010-05-14 2018-08-22 Orega Biotech Methods of treating and/or preventing cell proliferation disorders with il-17 antagonists
US9051619B2 (en) 2011-03-25 2015-06-09 Florida Agricultural and Mechanical University (FAMU) Methods and compositions for prostate cancer metastasis
SMT201800284T1 (it) 2011-06-10 2018-07-17 Univ Oregon Health & Science Glicoproteine cmv e vettori ricombinanti
EP2568289A3 (en) 2011-09-12 2013-04-03 International AIDS Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
EP2586461A1 (en) 2011-10-27 2013-05-01 Christopher L. Parks Viral particles derived from an enveloped virus
WO2013188870A2 (en) * 2012-06-15 2013-12-19 Beth Israel Deaconess Medical Center, Inc. IgA CD4i ANTIBODIES AND METHODS OF TREATMENT USING SAME
ES2631608T3 (es) 2012-06-27 2017-09-01 International Aids Vaccine Initiative Variante de la glicoproteína Env del VIH-1
US20140094383A1 (en) 2012-10-02 2014-04-03 Ohio State Innovation Foundation Tethered Lipoplex nanoparticle Biochips And Methods Of Use
WO2014201118A2 (en) 2013-06-11 2014-12-18 Sanford-Burnham Medical Research Institute Compositions and methods for targeted endometriosis treatment
EP2848937A1 (en) 2013-09-05 2015-03-18 International Aids Vaccine Initiative Methods of identifying novel HIV-1 immunogens
CN104418947A (zh) 2013-09-11 2015-03-18 香港大学 抗her2和抗-igf-ir的双特异性抗体及其用途
EP2873423B1 (en) 2013-10-07 2017-05-31 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
US9840555B2 (en) 2013-11-04 2017-12-12 Li-Te Chin Method for producing human monoclonal antibodies that binds to at least one part of HMGB1
CA2954475C (en) 2014-07-31 2023-05-16 Uab Research Foundation Apoe mimetic peptides and higher potency to clear plasma cholesterol
US10174292B2 (en) 2015-03-20 2019-01-08 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
US9931394B2 (en) 2015-03-23 2018-04-03 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
CN108779168A (zh) 2015-12-05 2018-11-09 沃迪奥斯大学医院中心 Hiv结合剂
KR102650803B1 (ko) 2016-10-05 2024-03-25 유니버시티 오브 센트럴 플로리다 리서치 파운데이션, 인코포레이티드 Nk 세포 및 항-pdl1 암 요법과 관련된 방법 및 조성물
CN118909082A (zh) 2017-03-28 2024-11-08 俄亥俄州创新基金会 一种分离的肽
US12025615B2 (en) 2017-09-15 2024-07-02 Arizona Board Of Regents On Behalf Of Arizona State University Methods of classifying response to immunotherapy for cancer
WO2019118686A1 (en) 2017-12-13 2019-06-20 North Carolina State University Compositions comprising chemotherapeutic agents and checkpoint inhibitors and methods of use
JP7579570B2 (ja) 2018-06-29 2024-11-08 ノース・キャロライナ・ステイト・ユニヴァーシティ 術後治療用ｉｎ ｓｉｔｕ噴霧生体応答性免疫療法ゲル
WO2020012435A1 (en) 2018-07-13 2020-01-16 Lausanne University Hospital Hiv binding agents
EP4588483A3 (en) 2018-10-03 2025-09-24 University of Pittsburgh- Of the Commonwealth System of Higher Education Covalent adaptor synnotch and chimeric antigen receptors (cars) for programmable antigen-targeting
US20220074951A1 (en) 2018-12-27 2022-03-10 University Of Utah Research Foundation Compositions and methods useful in detecting and treating multiple sclerosis and other demyelinating diseases
MX2021009020A (es) * 2019-01-28 2021-09-28 Xyphos Biosciences Inc Ligandos nkg2d no naturales modificados que entregan selectivamente moleculas heterologas unidas a receptores nkg2d no naturales en celulas car.
US12624091B2 (en) 2019-04-04 2026-05-12 Vanderbilt University HIV/HCV cross-reactive antibodies and uses thereof
WO2020206233A1 (en) 2019-04-04 2020-10-08 Vanderbilt University Therapeutic antibodies for treating lung cancer
WO2020236901A1 (en) 2019-05-20 2020-11-26 University Of Pittsburgh-Of The Commonwealth System Of Higher Education A novel therapy for erythropoietic protoporphyria (epp) and x-linked protoporphyria (xlp)
WO2020257640A1 (en) 2019-06-21 2020-12-24 Vaccinex, Inc. Combination therapy with semaphorin-4d blockade (sema4d) and dc1 therapy
EP3996815A2 (en) 2019-07-15 2022-05-18 Lausanne University Hospital Hiv binding agents
US12594278B2 (en) 2019-07-16 2026-04-07 Children's National Medical Center Method for treatment of muscular dystrophy
BR112022005044A2 (pt) 2019-09-17 2022-07-05 Ohio State Innovation Foundation Peptídeo quimérico, peptídeo sintético, composição farmacêutica, anticorpo, método de tratamento
EP4038222A4 (en) 2019-10-02 2023-10-18 Arizona Board of Regents on behalf of Arizona State University Methods and compositions for identifying neoantigens for use in treating and preventing cancer
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
CN115485392A (zh) 2020-01-24 2022-12-16 范德比尔特大学 用于鉴别配体阻断性抗体及用于确定抗体效价的方法
WO2021224687A1 (en) 2020-05-08 2021-11-11 Novocure Gmbh Compositions and methods of applying alternating electric fields to pluripotent stem cells
EP4153590A4 (en) 2020-05-21 2024-06-19 Ohio State Innovation Foundation FUNCTIONAL LIPID DERIVATIVES AND THEIR USES
EP4494660A3 (en) 2021-02-03 2025-04-16 Mythic Therapeutics, Inc. Anti-met antibodies and uses thereof
CN120712286A (zh) 2023-02-23 2025-09-26 翰森生物有限责任公司 抗体、抗原结合片段和使用方法
WO2025245128A1 (en) 2024-05-20 2025-11-27 Mythic Therapeutics, Inc. Antibody drug conjugates and therapeutic uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5652138A (en) * 1992-09-30 1997-07-29 The Scripps Research Institute Human neutralizing monoclonal antibodies to human immunodeficiency virus

Also Published As

Publication number Publication date
FI970198A7 (fi) 1997-03-17
JPH10505229A (ja) 1998-05-26
NO970221D0 (no) 1997-01-17
US5804440A (en) 1998-09-08
FI970198L (fi) 1997-03-17
US5652138A (en) 1997-07-29
AU2970095A (en) 1996-02-16
EP0777497A4 (en) 1998-01-07
EP0777497A1 (en) 1997-06-11
AU706601B2 (en) 1999-06-17
WO1996002273A1 (en) 1996-02-01
FI970198A0 (fi) 1997-01-17
CA2195454A1 (en) 1996-02-01

Similar Documents

Publication Publication Date Title
NO951212D0 (no) Humane nöytraliserende monoklonale antistoffer mot humant immunsviktvirus
DE69435126D1 (de) Synthetische humane neutralisierende monoklonale antikörper gegen hiv
NO970221D0 (no) Humane nöytraliserende monoklonale antistoffer mot humant immunsviktvirus
NL7800562A (nl) Rekenstelsel voor de beeldsynthese van een lichaamsdoorsnedebeeld, alsook een werkwijze voor het doen werken van het rekenstelsel.
FI883113A7 (fi) Menetelmä polyetyleenituotteiden valmistamiseksi, joille tuotteille o n ominaista suuri vetolujuus ja kimmomoduuli ja alhainen juoksevuus, ja siten saatuja tuotteita.
EP0671927A4 (en) HUMAN, NEUTRALIZING, MONOCLONAL ANTIBODIES AGAINST THE RESPIRATORY SYNCYTIAL VIRU.
TR25501A (tr) Kalorisi azaltilmis yaglari ihtiva eden tatlandir- ilmis sekerleme bilesimlerini kivamina getirmek icin islem ve böyle hazirlanan kivamlandirilmis mamuller.
DK0828717T3 (da) Fremgangsmåde til fremstilling af 3-haloalkyl-1H-pyrazol
NO306905B1 (no) Oligosakkarid avledet fra antigent polysakkarid erholdt fra et patogen
DE58900601D1 (de) Kampffahrzeug, insbesondere panzerhaubitze.
NL190818B (nl) Werkwijze en reagens voor de bepaling van alfa-amylase, alsmede werkwijze voor de bereiding van een maltoheptaosederivaat.
ATE427488T1 (de) Monoklonaler antikírper fur die inhibierung von hiv-1-hullgykoprotein-vermittelte membranfusion
SE8202106L (sv) Karbamidderivat
ES263109Y (es) Encendedor de gas.
NL7805377A (nl) Werkwijze voor het vervaardigen van koolstofvezels, alsmede de aldus vervaardigde koolstofvezels.
TW200517121A (en) Immunogen
NL191466B (nl) Voorlegering op basis van Al-Ti, alswel werkwijze voor de bereiding hiervan.
KR900009200A (ko) 관성 용접 방법, 그 방법에 의하여 제조된 제품 및 그 관성 용접 방법을 이용한 보수방법
NL190119B (nl) Werkwijze voor de bereiding van 4-hydroxy-5-alkyl- en 4-hydroxy-2,5-dialkyl-3-oxo-2h-furanen.
ES269197Y (es) Aparato de filtracion de gases por bolsas, perfeccionado.
NO883603D0 (no) Humane monoklonale antistoffer og profylaktiske og terapeutiske midler mot infektioese sykdommer inneholdende disse som effektiv bestanddel.
AU4959193A (en) High affinity, strongly neutralizing monoclonal antibodies against the CD-4 binding site of GP120 of human immunodeficiency virus
NL181794C (nl) Draagkettingtransporteur en een bochtsegment voor de loopbaan daarvan.
NL7809296A (nl) Werkwijze voor de volledige,selectieve n-acetylering van aminozuren door omzetting met keteen in waterige oplossing.
AU504726B1 (en) Solar. collector-refrigerant gas generator

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application